-
Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen
•
Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights to its anti-IL-7Rα biologic, bempikibart, from US-based Amgen (NASDAQ: AMGN). The biologic is currently in middle-stage trials for autoimmune diseases. This move follows Amgen’s acquisition of Horizon Therapeutics earlier this year, which had entered into…
-
Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry
•
Daewoong Pharma, a leading South Korean pharmaceutical company, has reportedly signed a memorandum of understanding (MoU) with China Meheco International, a move that will facilitate the export of Daewoong’s pharmaceutical products into the Chinese market. This comprehensive agreement encompasses the entire portfolio of Daewoong’s products, including their innovative in-house novel…
-
SinoMab BioScience’s Suciraslimab IND Accepted for Review by China’s NMPA
•
SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National Medical Products Administration (NMPA) in China has accepted its Investigational New Drug (IND) filing for suciraslimab for review. The company anticipates initiating a Phase I clinical study for the drug in the treatment of early…
-
Shanghai Henlius Biotech Reports 84.0% YOY Revenue Growth in Q3 2023 Financials
•
Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published its financial results for the third quarter of 2023. The company reported revenues of RMB 3.9278 billion (USD 542 million) for the nine months ending September 30, 2023, marking an impressive 84.0% year-on-year (YOY) increase.…
-
Sino Medical Sciences Technology’s HT Supreme Stent Gains Brazilian Market Approval
•
Sino Medical Sciences Technology Inc., (SHA: 688108) a leading China-based medical device company, has announced that its HT Supreme drug-eluting stent system has received market approval in Brazil. This system is designed to improve the diameter of the coronary artery lumen in patients suffering from symptomatic heart disease caused by…
-
Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies
•
Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership with Arcellx (NASDAQ: ACLX), a US-based biotechnology firm. The collaboration includes the in-licensing of ACLX-001, a multiple myeloma (MM) engineered cell therapy, and the extension of their CART-ddBCMA program to include lymphomas . Financial Terms…
-
AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management
•
US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group Co., Ltd, (HKG: 1099) a leading Chinese pharmaceutical company, to improve access to novel drugs and explore standardized patient management practices in China. Expanding Access and Patient SupportThe collaboration will utilize Sinopharm’s extensive SPS+ professional…
-
Fujian Cosunter’s COVID-19 Therapy GST-HG171/Ritonavir NDA Accepted by NMPA
•
Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that its New Drug Application (NDA) for the Category 1 product GST-HG171/ritonavir, an oral therapy for COVID-19, has been accepted for review by China’s National Medical Products Administration (NMPA). Therapeutic Profile of GST-HG171/RitonavirGST-HG171 is identified as a…
